• ABL Diagnostics set a Sept. 17 shareholder vote on shifting its shares from Euronext Paris to Euronext Growth Paris.
• Move targets lower compliance costs, simpler reporting, and a market better matched to its size and trading profile.
• Transfer would use an accelerated admission of existing shares, with no new shares issued.
• Free float stood at 5.99%, valued at EUR 2.41 million at a EUR 2.5 close on Aug. 6; company expects to meet eligibility by transfer.
• Trading on Euronext Growth could start no earlier than Nov. 17, subject to shareholder backing and Euronext clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ABL Diagnostics SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202608071200BIZWIRE_USPR_____20260807_BW148066) on August 07, 2026, and is solely responsible for the information contained therein.